| Rank |
Title |
Year |
PubWeight™‹?› |
|
1
|
Castration-resistant prostate cancer: mechanisms, targets, and treatment.
|
2012
|
1.47
|
|
2
|
Recent trends in prostate cancer incidence by age, cancer stage, and grade, the United States, 2001-2007.
|
2012
|
1.38
|
|
3
|
Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent.
|
2013
|
1.37
|
|
4
|
A retrospective study on pathologic features and racial disparities in prostate cancer.
|
2011
|
1.17
|
|
5
|
Prostate cancer incidence rates in Africa.
|
2011
|
1.15
|
|
6
|
Prostate cancer incidence and mortality in barbados, west indies.
|
2011
|
1.07
|
|
7
|
Mouse models of prostate cancer.
|
2011
|
1.04
|
|
8
|
Markers of field cancerization: proposed clinical applications in prostate biopsies.
|
2012
|
1.00
|
|
9
|
Hypofractionated external-beam radiotherapy for prostate cancer.
|
2013
|
0.99
|
|
10
|
Racial/Ethnic patterns in prostate cancer outcomes in an active surveillance cohort.
|
2011
|
0.96
|
|
11
|
Circulating MicroRNAs as Biomarkers of Prostate Cancer: The State of Play.
|
2013
|
0.96
|
|
12
|
Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer.
|
2013
|
0.94
|
|
13
|
The Metabolic Syndrome and Biochemical Recurrence following Radical Prostatectomy.
|
2011
|
0.94
|
|
14
|
Rectourinary fistula after radical prostatectomy: review of the literature for incidence, etiology, and management.
|
2011
|
0.93
|
|
15
|
Epigenetics in prostate cancer.
|
2011
|
0.92
|
|
16
|
The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton.
|
2013
|
0.92
|
|
17
|
Metastasis Update: Human Prostate Carcinoma Invasion via Tubulogenesis.
|
2011
|
0.92
|
|
18
|
Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms.
|
2013
|
0.91
|
|
19
|
Review of small cell carcinomas of the prostate.
|
2011
|
0.91
|
|
20
|
Prostate cancer severity associations with neighborhood deprivation.
|
2011
|
0.90
|
|
21
|
Paradoxical roles of tumour necrosis factor-alpha in prostate cancer biology.
|
2012
|
0.90
|
|
22
|
Beyond diagnosis: evolving prostate biopsy in the era of focal therapy.
|
2010
|
0.89
|
|
23
|
Androgen receptor-target genes in african american prostate cancer disparities.
|
2013
|
0.88
|
|
24
|
Racial disparities in prostate cancer incidence, biochemical recurrence, and mortality.
|
2011
|
0.87
|
|
25
|
Relationship of dietary intake of omega-3 and omega-6 Fatty acids with risk of prostate cancer development: a meta-analysis of prospective studies and review of literature.
|
2012
|
0.86
|
|
26
|
Long-term (10-year) gastrointestinal and genitourinary toxicity after treatment with external beam radiotherapy, radical prostatectomy, or brachytherapy for prostate cancer.
|
2012
|
0.85
|
|
27
|
3D versus 2D Systematic Transrectal Ultrasound-Guided Prostate Biopsy: Higher Cancer Detection Rate in Clinical Practice.
|
2013
|
0.85
|
|
28
|
Primary Zonal High Intensity Focused Ultrasound for Prostate Cancer: Results of a Prospective Phase IIa Feasibility Study.
|
2014
|
0.85
|
|
29
|
Prognostic factors for the development of biochemical recurrence after radical prostatectomy.
|
2011
|
0.85
|
|
30
|
Prostate cancer in South Africa: pathology based national cancer registry data (1986-2006) and mortality rates (1997-2009).
|
2014
|
0.85
|
|
31
|
HMGB1: A Promising Therapeutic Target for Prostate Cancer.
|
2013
|
0.85
|
|
32
|
Hypofractionated proton boost combined with external beam radiotherapy for treatment of localized prostate cancer.
|
2012
|
0.84
|
|
33
|
Phase I Study of Anti-CD3 x Anti-Her2 Bispecific Antibody in Metastatic Castrate Resistant Prostate Cancer Patients.
|
2015
|
0.84
|
|
34
|
Current challenges in development of differentially expressed and prognostic prostate cancer biomarkers.
|
2012
|
0.84
|
|
35
|
Emerging molecularly targeted therapies in castration refractory prostate cancer.
|
2013
|
0.83
|
|
36
|
Role of signaling transduction pathways in development of castration-resistant prostate cancer.
|
2011
|
0.83
|
|
37
|
Emerging putative biomarkers: the role of alpha 2 and 6 integrins in susceptibility, treatment, and prognosis.
|
2012
|
0.83
|
|
38
|
Postoperative radiotherapy after radical prostatectomy: indications and open questions.
|
2012
|
0.83
|
|
39
|
Analysis of preoperative detection for apex prostate cancer by transrectal biopsy.
|
2013
|
0.83
|
|
40
|
Frequency of positive surgical margin at prostatectomy and its effect on patient outcome.
|
2011
|
0.82
|
|
41
|
Incidentally found prostate cancer and influence on overall survival after radical cystoprostatectomy.
|
2012
|
0.82
|
|
42
|
Factors implicated in radiation therapy failure and radiosensitization of prostate cancer.
|
2011
|
0.82
|
|
43
|
Does Statin or ASA Affect Survival When Prostate Cancer Is Treated with External Beam Radiation Therapy?
|
2014
|
0.82
|
|
44
|
Comments on the extraperitoneal approach for standard laparoscopic radical prostatectomy: what is gained and what is lost.
|
2011
|
0.82
|
|
45
|
Growth and Progression of TRAMP Prostate Tumors in Relationship to Diet and Obesity.
|
2012
|
0.82
|
|
46
|
Personalized management in low-risk prostate cancer: the role of biomarkers.
|
2012
|
0.82
|
|
47
|
Pros and cons of focal therapy for localised prostate cancer.
|
2011
|
0.82
|
|
48
|
Androgen Metabolism Gene Polymorphisms, Associations with Prostate Cancer Risk and Pathological Characteristics: A Comparative Analysis between South African and Senegalese Men.
|
2012
|
0.82
|
|
49
|
Laparoscopic sentinel lymph node biopsy for prostate cancer: the relevance of locations outside the extended dissection area.
|
2011
|
0.81
|
|
50
|
Triptorelin in the Relief of Lower Urinary Tract Symptoms in Advanced Prostate Cancer Patients: The RESULT Study.
|
2015
|
0.81
|